Small Non-cleaved Cell Lymphoma News

Small Non-cleaved Cell Lymphoma	Welcome, Profile Billing Logout

«1 2...2 3 4 5 6 7 8 91011 12 13 14 »

|||||||||| Enrollment closed: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (clinicaltrials.gov) - Jul 8, 2013
P1, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recruiting --> Active, not recruiting

||||||||||  obatoclax (GX 15-070) / Teva
Trial termination, Combination therapy:  Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (clinicaltrials.gov) -  Jun 30, 2013
P1, N=22, Terminated,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated

||||||||||  sirolimus / Generic mfg.
Trial suspension:  Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Jun 30, 2013
P1, N=10, Suspended,  Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Terminated Recruiting --> Suspended

||||||||||  sirolimus / Generic mfg.
Enrollment change:  Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Jun 30, 2013
P1, N=10, Suspended,  Sponsor: Children's Hospital of Philadelphia
Recruiting --> Suspended N=30 --> 10

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion:  Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma (clinicaltrials.gov) -  Jun 30, 2013
P1, N=20, Completed,  Sponsor: National Cancer Institute (NCI)
N=30 --> 10 Active, not recruiting --> Completed

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases:  Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (clinicaltrials.gov) -  Jun 30, 2013
P1, N=15, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion:  Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) -  Jun 30, 2013
P1, N=30, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial suspension: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jun 27, 2013
P2, N=38, Suspended, Sponsor: University of Medicine and Dentistry New Jersey
Active, not recruiting --> Completed Not yet recruiting --> Suspended

|||||||||| Trial initiation date: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jun 27, 2013
P2, N=38, Suspended, Sponsor: University of Medicine and Dentistry New Jersey
Not yet recruiting --> Suspended Initiation date: Dec 2012 --> Jan 2014

|||||||||| Enrollment change, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Initiation date: Dec 2012 --> Jan 2014 N=64 --> 80

||||||||||  paclitaxel / Generic mfg.
Trial completion, Combination therapy:  Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) -  Jun 19, 2013
P1, N=40, Completed,  Sponsor: Memorial Sloan-Kettering Cancer Center
N=64 --> 80 Active, not recruiting --> Completed

||||||||||  picoplatin (AMD 473) / Accelerated Pharma
Trial completion, Metastases:  ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) -  Jun 16, 2013
P1, N=0, Completed,  Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy (clinicaltrials.gov) - Jun 9, 2013
P1, N=20, Completed, Sponsor: University of Louisville
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  Rituxan (rituximab) / Roche
Trial completion:  Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer (clinicaltrials.gov) -  Jun 4, 2013
P1, N=30, Completed,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Biomarker, Enrollment closed: AALL12B3: Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2013
P=N/A, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting

||||||||||  Kepivance (palifermin) / SOBI, Amgen
Enrollment change:  Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant (clinicaltrials.gov) -  May 29, 2013
P2, N=0, Withdrawn,  Sponsor: Children's Oncology Group
Not yet recruiting --> Active, not recruiting N=200 --> 0

||||||||||  alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy:  Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  May 20, 2013
P2, N=50, Recruiting,  Sponsor: Kristie Blum
N=200 --> 0 Not yet recruiting --> Recruiting

||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion:  Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (clinicaltrials.gov) -  May 20, 2013
P1, N=66, Completed,  Sponsor: Pharmacyclics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| Trial termination: Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer (clinicaltrials.gov) - May 19, 2013
P2, N=9, Terminated, Sponsor: University of South Florida
Completed --> Terminated; study not feasible with low accrual. DSMB recommended closure

|||||||||| Enrollment change: Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer (clinicaltrials.gov) - May 19, 2013
P2, N=9, Terminated, Sponsor: University of South Florida
DSMB recommended closure N=250 --> 9

|||||||||| Trial completion: SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 16, 2013
P=N/A, N=458, Completed, Sponsor: Southwest Oncology Group
N=250 --> 9 Active, not recruiting --> Completed

|||||||||| Trial completion: SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial (clinicaltrials.gov) - May 16, 2013
P=N/A, N=32, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Bexxar (iodine I 131 tositumomab) / GSK, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change:  Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  May 14, 2013
P=N/A, N=9, Completed,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=88 --> 9

||||||||||  Bexxar (iodine I 131 tositumomab) / GSK, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion:  Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  May 14, 2013
P=N/A, N=9, Completed,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=88 --> 9 Recruiting --> Completed

||||||||||  Beleodaq (belinostat) / Aurobindo, Assertio
Trial termination, Combination therapy, Metastases:  PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (clinicaltrials.gov) -  May 14, 2013
P1, N=36, Terminated,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated

||||||||||  RG4733 / Roche
Trial initiation date, Combination therapy:  RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) -  May 14, 2013
P1, N=30, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Nov 2009 --> Jun 2010

||||||||||  RG4733 / Roche
Enrollment closed, Combination therapy:  RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) -  May 14, 2013
P1, N=30, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2009 --> Jun 2010 Recruiting --> Active, not recruiting

||||||||||  bortezomib / Generic mfg.
Trial completion, Metastases:  Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction (clinicaltrials.gov) -  May 14, 2013
P1, N=69, Completed,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial termination: Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant (clinicaltrials.gov) - May 10, 2013
P1, N=252, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Completed --> Terminated; study closed prematurely upon PI's departure from VICC

||||||||||  melphalan / Generic mfg., busulfan / Generic mfg., thiotepa / Generic mfg.
Enrollment closed:  Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  May 9, 2013
P2, N=37, Active, not recruiting,  Sponsor: OHSU Knight Cancer Institute
Completed --> Terminated; study closed prematurely upon PI's departure from VICC Completed --> Active, not recruiting

|||||||||| Trial completion: Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant (clinicaltrials.gov) - May 9, 2013
P=N/A, N=459, Completed, Sponsor: City of Hope Medical Center
Completed --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial initiation date: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Initiation date: Jul 1991 --> Dec 1991

|||||||||| Trial completion: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Initiation date: Jul 1991 --> Dec 1991 Active, not recruiting --> Completed

||||||||||  RG4733 / Roche
Trial termination:  Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (clinicaltrials.gov) -  Apr 30, 2013
P1/2, N=129, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated

|||||||||| Trial termination: Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Apr 30, 2013
P1, N=40, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Active, not recruiting --> Terminated

|||||||||| Trial completion: Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (clinicaltrials.gov) - Apr 29, 2013
P1, N=60, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated Active, not recruiting --> Completed

||||||||||  Monjuvi (tafasitamab-cxix) / Incyte
Enrollment open:  Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov) -  Apr 28, 2013
P2a, N=30, Recruiting,  Sponsor: MorphoSys AG
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Trial completion, HEOR: Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer (clinicaltrials.gov) - Apr 28, 2013
P2, N=750, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  melphalan / Generic mfg., amifostine / Generic mfg.
Trial completion:  Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect (clinicaltrials.gov) -  Apr 24, 2013
P1/2, N=25, Completed,  Sponsor: University of Kentucky
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change:  Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma (clinicaltrials.gov) -  Apr 16, 2013
P2, N=10, Terminated,  Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed N=30 --> 10

||||||||||  Amplimexon (imexon) / Amplimed Corp
Enrollment closed:  Imexon for Relapsed Follicular and Aggressive Lymphomas (clinicaltrials.gov) -  Apr 16, 2013
P2, N=18, Active, not recruiting,  Sponsor: University of Rochester
N=30 --> 10 Recruiting --> Active, not recruiting

||||||||||  Gliadel Wafer (carmustine implant) / Eisai, Azurity Pharma, Rituxan (rituximab) / Roche
Enrollment closed:  Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Apr 16, 2013
P2, N=68, Active, not recruiting,  Sponsor: University of Nebraska
Recruiting --> Active, not recruiting Completed --> Active, not recruiting

|||||||||| Trial termination: Studying Fentanyl in Patients With Cancer (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Completed --> Active, not recruiting Recruiting --> Terminated; poor accrual

|||||||||| Enrollment change: Studying Fentanyl in Patients With Cancer (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Terminated; poor accrual N=20 --> 2

||||||||||  pegylated liposomal doxorubicin / Generic mfg.
Trial completion:  Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Apr 9, 2013
P1, N=48, Completed,  Sponsor: University of Alabama at Birmingham
N=20 --> 2 Active, not recruiting --> Completed

||||||||||  Rituxan (rituximab) / Roche
Trial termination:  S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Apr 7, 2013
P3, N=7, Terminated,  Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Completed --> Terminated; lack of accrual

||||||||||  Yervoy (ipilimumab) / BMS
Trial completion, IO biomarker:  MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) -  Apr 7, 2013
P1/2, N=36, Completed,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; lack of accrual Terminated --> Completed

||||||||||  lenalidomide / Generic mfg.
Enrollment change:  Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) -  Mar 25, 2013
P1, N=60, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Terminated --> Completed N=90 --> 60

||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial completion:  Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer (clinicaltrials.gov) -  Mar 20, 2013
P2, N=40, Completed,  Sponsor: Cancer Treatment Centers of America
N=90 --> 60 Active, not recruiting --> Completed

||||||||||  ifosfamide / Generic mfg., carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion:  Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer (clinicaltrials.gov) -  Mar 20, 2013
P1/2, N=30, Completed,  Sponsor: Cancer Treatment Centers of America
Active, not recruiting --> Completed Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites